JP4455760B2 - 特定の薬物の硝酸エステル及び硝酸塩 - Google Patents
特定の薬物の硝酸エステル及び硝酸塩 Download PDFInfo
- Publication number
- JP4455760B2 JP4455760B2 JP2000562338A JP2000562338A JP4455760B2 JP 4455760 B2 JP4455760 B2 JP 4455760B2 JP 2000562338 A JP2000562338 A JP 2000562338A JP 2000562338 A JP2000562338 A JP 2000562338A JP 4455760 B2 JP4455760 B2 JP 4455760B2
- Authority
- JP
- Japan
- Prior art keywords
- nitrate
- solution
- acetonitrile
- salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940079593 drug Drugs 0.000 title description 5
- 239000003814 drug Substances 0.000 title description 5
- 150000002823 nitrates Chemical class 0.000 title description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 49
- 229910002651 NO3 Inorganic materials 0.000 claims description 45
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229960001803 cetirizine Drugs 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims 1
- LFLZOWIFJOBEPN-UHFFFAOYSA-N nitrate, nitrate Chemical compound O[N+]([O-])=O.O[N+]([O-])=O LFLZOWIFJOBEPN-UHFFFAOYSA-N 0.000 claims 1
- 229960001402 tilidine Drugs 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 42
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 150000003839 salts Chemical class 0.000 description 30
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 19
- 229910017604 nitric acid Inorganic materials 0.000 description 19
- 239000007787 solid Substances 0.000 description 17
- 238000000921 elemental analysis Methods 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 229960002052 salbutamol Drugs 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 239000011877 solvent mixture Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 229960005174 ambroxol Drugs 0.000 description 9
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical class COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 9
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960001985 dextromethorphan Drugs 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- 229960002504 capsaicin Drugs 0.000 description 4
- 235000017663 capsaicin Nutrition 0.000 description 4
- 229960000325 emedastine Drugs 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229960003350 isoniazid Drugs 0.000 description 4
- 229960004958 ketotifen Drugs 0.000 description 4
- 229960003088 loratadine Drugs 0.000 description 4
- 229960000282 metronidazole Drugs 0.000 description 4
- 230000000510 mucolytic effect Effects 0.000 description 4
- 229960004398 nedocromil Drugs 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 230000002082 anti-convulsion Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 3
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- -1 silver halide Chemical class 0.000 description 3
- 229910001961 silver nitrate Inorganic materials 0.000 description 3
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- SNDDIRAXSDUVKW-URVXVIKDSA-N dextromethorphan hcl Chemical compound Cl.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 SNDDIRAXSDUVKW-URVXVIKDSA-N 0.000 description 2
- 229960005257 dextromethorphan hydrochloride Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- FUDNDQOAKRSNFG-UHFFFAOYSA-N nitric acid;pyrazine-2-carboxamide Chemical compound O[N+]([O-])=O.NC(=O)C1=CN=CC=N1 FUDNDQOAKRSNFG-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- IOKIELYKONFEPP-UHFFFAOYSA-N 1-bromohex-1-yne Chemical compound CCCCC#CBr IOKIELYKONFEPP-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/04—Payment circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/44—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton bound to carbon atoms of the same ring or condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/86—Hydrazides; Thio or imino analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/22—Payment schemes or models
- G06Q20/24—Credit schemes, i.e. "pay after"
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/38—Payment protocols; Details thereof
- G06Q20/40—Authorisation, e.g. identification of payer or payee, verification of customer or shop credentials; Review and approval of payers, e.g. check credit lines or negative lists
- G06Q20/401—Transaction verification
- G06Q20/4014—Identity check for transactions
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/38—Payment protocols; Details thereof
- G06Q20/40—Authorisation, e.g. identification of payer or payee, verification of customer or shop credentials; Review and approval of payers, e.g. check credit lines or negative lists
- G06Q20/403—Solvency checks
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q40/00—Finance; Insurance; Tax strategies; Processing of corporate or income taxes
- G06Q40/02—Banking, e.g. interest calculation or account maintenance
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07C—TIME OR ATTENDANCE REGISTERS; REGISTERING OR INDICATING THE WORKING OF MACHINES; GENERATING RANDOM NUMBERS; VOTING OR LOTTERY APPARATUS; ARRANGEMENTS, SYSTEMS OR APPARATUS FOR CHECKING NOT PROVIDED FOR ELSEWHERE
- G07C9/00—Individual registration on entry or exit
- G07C9/30—Individual registration on entry or exit not involving the use of a pass
- G07C9/32—Individual registration on entry or exit not involving the use of a pass in combination with an identity check
- G07C9/37—Individual registration on entry or exit not involving the use of a pass in combination with an identity check using biometric data, e.g. fingerprints, iris scans or voice recognition
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/20—Servers specifically adapted for the distribution of content, e.g. VOD servers; Operations thereof
- H04N21/25—Management operations performed by the server for facilitating the content distribution or administrating data related to end-users or client devices, e.g. end-user or client device authentication, learning user preferences for recommending movies
- H04N21/254—Management at additional data server, e.g. shopping server, rights management server
- H04N21/2543—Billing, e.g. for subscription services
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/41—Structure of client; Structure of client peripherals
- H04N21/418—External card to be used in combination with the client device, e.g. for conditional access
- H04N21/4185—External card to be used in combination with the client device, e.g. for conditional access for payment
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/41—Structure of client; Structure of client peripherals
- H04N21/422—Input-only peripherals, i.e. input devices connected to specially adapted client devices, e.g. global positioning system [GPS]
- H04N21/4223—Cameras
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/43—Processing of content or additional data, e.g. demultiplexing additional data from a digital video stream; Elementary client operations, e.g. monitoring of home network or synchronising decoder's clock; Client middleware
- H04N21/441—Acquiring end-user identification, e.g. using personal code sent by the remote control or by inserting a card
- H04N21/4415—Acquiring end-user identification, e.g. using personal code sent by the remote control or by inserting a card using biometric characteristics of the user, e.g. by voice recognition or fingerprint scanning
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N21/00—Selective content distribution, e.g. interactive television or video on demand [VOD]
- H04N21/40—Client devices specifically adapted for the reception of or interaction with content, e.g. set-top-box [STB]; Operations thereof
- H04N21/47—End-user applications
- H04N21/478—Supplemental services, e.g. displaying phone caller identification, shopping application
- H04N21/47815—Electronic shopping
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
- H04N7/00—Television systems
- H04N7/16—Analogue secrecy systems; Analogue subscription systems
- H04N7/173—Analogue secrecy systems; Analogue subscription systems with two-way working, e.g. subscriber sending a programme selection signal
- H04N7/17309—Transmission or handling of upstream communications
- H04N7/17318—Direct or substantially direct transmission and handling of requests
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Description
この発明は、感染性の病因病理学に基づいているか又はそれに基づいていない呼吸系の病状、特に、喘息、気管支炎、エンフィセマ(enphisema)、血栓塞栓のような慢性肺疾患(慢性閉塞性肺疾患(COPD))の治療に用いられる、これらの病状の治療に現在用いられている薬物と比較して副作用の低い、全身及び非全身的な用途のための化合物又はその医薬組成物に関する。
【0002】
これらの病状の治療にもっとも用いられている製品がサルブタモール、サルメテロール(salmeterol)などであることは、当該分野で公知である(例えば“Textbook of Therapeutics − Drugs and Disease Management − 第6版、1996”685頁参照)。これらの製品は有効であるが、特に心血管器官に副作用を生ずる欠点がある。これらの製品は、心血管の病状に罹患している患者には用心して投与しなければならない。
それ自体で又は他の薬品の共助剤(coadjuvant)としてこれらの病状に用いられている他の製品は、例えばアンブロキソール及びブロモヘキシンである。これらの投与は、焼け付き及び胃過敏症のような胃腸器官に対する副作用をも伴う。
【0003】
心血管器官及び/又は胃腸器官に対する副作用の低下と組合わさった、呼吸系病状の治療に有効な化合物及び医薬組成物を利用可能にする必要があった。
本出願人は、予期しなかったことにかつ驚くべきことに、上記技術的課題を解決する特定の化合物及びその組成物を見出した。
【0004】
この発明の対象は、呼吸系病状、特に喘息、気管支炎、エンフィセマ、血栓塞栓のような慢性肺疾患(慢性閉塞性肺疾患(COPD))、感染性肺疾患の治療に用いられる化合物の硝酸塩又はその医薬組成物である。これらの化合物は、硝酸で塩にされうる反応基を少なくとも1つ含むことを特徴とし、以下から選択される:
-式(I)のサルブタモール
【化22】
【0005】
-式(II)のセチリジン(cetrezin)
【化23】
【0006】
-式(III)のロラタジン
【化24】
【0007】
-式(IV)のテルフェナンジン
【化25】
【0008】
-式(V)のエメダスチン
【化26】
【0009】
-式(VI)のケトチフェン
【化27】
【0010】
-式(VII)のネドクロミル(nedocromil)
【化28】
【0011】
-式(VIII)のアンブロキソール
【化29】
【0012】
-式(IX)のブロモヘキシン
【化30】
【0013】
-式(X)のデキストロメトルファン
【化31】
【0014】
-式(XI)デキストロファン(dextrophan)
【化32】
【0015】
-式(XII)のメトロニダゾール
【化33】
【0016】
-式(XIII)のイソニアジド
【化34】
【0017】
-式(XIV)のエリスロマイシン
【化35】
【0018】
-式(XV)のアシクロビル
【化36】
【0019】
-式(XVI)のピラジナミド
【化37】
【0020】
好ましい化合物は、アルブテロール(albuterol)としても公知のサルブタモール、セチリジン、エメダスチン、アンブロキソールである。
この発明の硝酸塩は、上述の化合物を用いても得ることができ、これらは、任意に、以下の二価の架橋結合の1つによって分子に共有結合される1以上の-ONO2基を含んでいてもよい:
- YO、ここで、Yは可能であればC1-C20、好ましくは炭素原子が2〜5の線状又は分枝状のアルキレン、又は炭素原子が5〜7個の任意に置換されたシクロアルキレンである;
【化38】
[式中、n3は0〜3の整数である];
【0021】
【化39】
【0022】
【化40】
【0023】
【化41】
【0024】
[式中、nf'は1〜6、好ましくは2〜4の整数である];
【化42】
【0025】
[式中、R1fはH、CH3かつnfは1〜6、好ましくは2〜4の整数である]
から選択されるY1。
上記の二価の架橋結合の1つによって分子に共有結合される-ONO2基を含むこれらの化合物は、ここで参照によって導入される本出願人名義の特許出願WO 95/30641号に記載されているようにして製造される。
また、この発明の組成物では、入手可能な際には、上記化合物の1以上の異性体(光学異性体含む)を用いることができる。
異性体の例は、シス、トランス、D及びLの光学異性体又はラセミ、鏡像異性体である。一般に、1つの異性体型は他方より活性が高く、例えばD型はL型より活性が高く、D型よりL型の活性が高い場合もある。
【0026】
この発明の塩は、少なくとも1つの硝酸イオンモル/前駆体モルを含む。好ましくは、硝酸イオンモルと前駆体モルの比率は、単一である。硝酸アニオンでイオン結合を形成するのに十分塩基性な他のアミン基が分子にある際に、分子比率が高い塩が得られる。
この発明の塩は、通常の賦形剤(例えば“Remington's Pharmaceutical Science 15a Ed.”参照)とともに、この分野で公知の技術にしたがって相当する医薬組成物に製剤化される。
上述の群に属する塩の前駆体は、ここに参照により導入されるMerck Index 14a版に記載の方法にしたがって製造される。
【0027】
この発明の塩は、以下の方法の1つによって得ることができる。
この発明にしたがって塩を形成するのに用いられる前駆体が有機溶媒(好ましくは水酸基を分子中に含まない、例えばアセトニトリル、酢酸エチル、テトラヒドロフラン等)中でともに可溶性の遊離の塩基又は相当する塩として入手できる際は、硝酸塩は、物質又はその塩を好ましくは10%w/vに等しい又はそれより高い濃度で溶媒に溶解し、次いで、必要量の濃硝酸を好ましくは化合物を溶解するのに先に用いたのと同じ溶媒中に希釈して加え、好ましくは、添加のあいだ及びその後に、混合物を20℃から0℃に冷却し、生じた生成物をろ過で回収し、任意に同じ冷却溶媒で固体を洗浄して製造される。
前駆体又はその入手可能な塩が、上記溶媒にわずかに可溶性である際には、水酸化溶媒を上記溶媒に加え、溶解性を改善する。このような水酸化溶媒の例には、メチルアルコール、エチルアルコール及び水がある。硝酸を加えた後に無極性溶媒で希釈して、沈澱を早めることができる。
【0028】
前駆体がハロゲン化水素で塩にされる際には、上記溶媒中のハロゲン化物の溶液に硝酸銀を直接加えて硝酸との塩を製造することができる。ハロゲン化銀をろ去後、溶液を濃縮して冷却し、硝酸塩を沈澱により回収する。
しかし、アニオンが塩素と異なる前駆体の塩を原料とする際には、炭酸又は重炭酸のナトリウムもしくはカリウムの飽和塩の溶液で、又は希釈した水酸化ナトリウムもしくは水酸化カリウムの溶液で塩の水溶液を処理し、次いで、適当な有機溶媒(例えばハロゲン化溶媒、エステル、エーテル)で水相を抽出して脱水し、次に有機溶液を蒸発させ、こうして得た残渣を、水酸基を含まない上記溶媒、例えばアセトニトリル又は水酸化溶媒とこの溶媒との混合物に溶解し、次に上述の製造方法を続行することが好ましい。
【0029】
この発明の塩及び組成物は、全身的な投与に用いることができる。例えば、それらは去痰薬のような経口経路によって;筋肉内、静脈経路などによって投与することができ;あるいは、例えばエアロゾルもしくは局所塗布のような非全身的な投与に用いてもよい。一般に、この発明の塩は、前駆体と同じ治療適用に用いられる。
この発明の硝酸塩は、前駆体に対比して一般的な安全性を増す。
投与量は、前駆体についての一般的な用量である。しかし、この発明の生成物は前駆体より優れた治療効力を示すので、副作用を生じずに前駆体の用量より多い用量でも用いることができる。
この発明の生成物の他の適用には、早産防止薬(tokolitics)(抗痙攣)として、例えば子宮筋系抗痙攣、腸筋系抗痙攣;例えば眼に適用するための抗ヒスタミン(抗アレルギー);感染性呼吸疾患用の鎮咳、抗菌がある。それらは、上記のとおり、全身経路もしくは非全身経路によって、又は洗眼剤等のような眼組成物の形態でも投与することができる。
【0030】
この発明を例示するためにのみ、以下に実施例を示す。実施例は、この発明を限定するものではない。
実施例1:アンブロキソール硝酸塩の製造
アンブロキソール溶液(4g、20.6mmol)はアセトニトリル(30ml)とテトラヒドロフラン(10ml)の混合物に溶解して製造する。低温度(4℃)で、アセトニトリルで希釈した硝酸を加える(65%硝酸2.7mlにアセトニトリルを加え、アセトニトリルで最終用量を10mlにして得た溶液から3.5ml採取)。30分後、エチルエーテル(100ml)を同温(+4℃)でゆっくり加える。生じた沈殿物をろ過し、エチルエーテルで洗浄して真空乾燥する。白色の非晶質固体が得られる。これは、元素分析によればアンブロキソールの硝酸塩に相当する:
【数1】
【0031】
実施例2:サルブタモール硝酸塩の製造
アセトニトリル(30ml)とテトラヒドロフラン(10ml)中のサルブタモール溶液(4g、16.7mmol)を原料とし、アセトニトリル中の硝酸溶液4ml及び実施例1と同じ方法を用いて、非晶質固体を得る。これは、元素分析によれば、サルブタモールの硝酸塩に相当する:
【数2】
【0032】
薬理試験
実施例3:この発明の塩の急性毒性研究
生成物は、各10匹のマウスの群に2重量%のカルボキシメチルセルロース懸濁液で投与する。
塩の急性毒性は、各10匹のラットの群に単一用量の化合物を経口投与して評価し、100mg/kgまで増加させた。
動物を14日間観察下に置き、病変の発生と毒性症状の顕在化を記録した。
100mg/kg用量の投与後にも、明らかな毒性の徴候は認められていない。
【0033】
実施例4:モルモットの実験的な気管支収縮におけるサルブタモールとサルブタモール硝酸塩の作用の研究
動物は、心肺活性測量についてのDel Soldatoらの方法(J.Pharmacol. Methods 5 279 1981)にしたがって用意した。各群は、8匹の動物で構成した。カプサイシンの塩溶液(1μg/kg) 0.1mlを静脈経路で動物に注射した。全15分について、カプサイシンの注射の5分前から注射から10分後に、サルブタモール(0.3nmol/分)又は相当する硝酸塩(0.3nmol/分)又は担体のみを開始物質として、静脈注入により各群に投与した。
上記のDel Soldatoの参考文献に記載されているようにポリグラフシステムに接続して変えたコンツェット(Konzett)装置によって、カプサイシン投与前後の一回換気量の変化を測定した。
【0034】
心拍数は、通常の方法にしたがって電気カルジオグラフ装置で測定した。結果を表1に示す。賦形剤を投与した後の心拍数の平均値は、188±7拍/分であった。反応は、対照に対する%値として示す。
表1に示すように、サルブタモール硝酸塩は、カプサイシンによって誘導される気管支収縮の反応阻害においてサルブタモールと同じくらい有効であるが、その塩は、サルブタモールに関してより耐性(脈拍反応がない)である。
【表1】
【0035】
実施例5:セトリジン硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(5ml)からなる溶媒混合物にセチリジン溶液(2g、5.14mmol)を加えて製造する(アセトニトリル中の硝酸溶液1.23mlは実施例1に記載した)。非晶質固体が得られ、それは、元素分析によればセチリジン硝酸塩に相当する:
【数3】
【0036】
実施例6:ロラタジン硝酸塩の製造
塩は、アセトニトリル(7ml)とテトラヒドロフラン(3ml)からなる溶媒混合物にロラタジン溶液(1g、2.61mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.63mlは実施例1に記載した)。元素分析では、得られた固体はロラタジン硝酸塩に相当する:
【数4】
【0037】
実施例7:テルフェナンジン硝酸塩の製造
塩は、アセトニトリル(15ml)とテトラヒドロフラン(5ml)からなる溶媒混合物にテルフェナンジン溶液(1.5g、3.18mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.76mlは実施例1に記載した)。元素分析では、得られた固体はテルフェナンジン硝酸塩に相当する:
【数5】
【0038】
実施例8:エメダスチン硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(7ml)からなる溶媒混合物にエメダスチン溶液(2g、5.47mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.7mlは実施例1に記載した)。元素分析では、得られた固体はエメダスチン硝酸塩に相当する:
【数6】
【0039】
実施例9:ブロモヘキシン硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(10ml)からなる溶媒混合物にブロモヘキシン溶液(2g、5.17mmol)を加えて製造する(アセトニトリル中の硝酸溶液1.24mlは実施例1に記載した)。元素分析では、得られた固体はブロモヘキシン硝酸塩に相当する:
【数7】
【0040】
実施例10:デキストロメトルファン硝酸塩の製造
塩は、アセトニトリル(20ml)中のデキストロメトルファン臭化水素溶液(2g、5.68mmol)に硝酸銀(0.96g、5.68mmol)を加えて製造する。次いで、溶液を30分室温で攪拌する。次に、ろ過して臭化銀の沈殿物を除く。エチルエーテルの透明な溶液を加える(110ml)。沈澱が生じ、これをろ過し、エチルエーテルで洗浄して真空乾燥する。元素分析では、得られた固体はデキストロメトルファン硝酸塩に相当する:
【数8】
【0041】
実施例11:ケトチフェン硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(5ml)からなる溶媒混合物にケトチフェン溶液(1g、3.23mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.78mlは実施例1に記載した)。元素分析では、得られた固体はケトチフェン硝酸塩に相当する:
【数9】
【0042】
実施例12:ネドクロミル硝酸塩の製造
塩は、アセトニトリル(7ml)とテトラヒドロフラン(5ml)からなる溶媒混合物にネドクロミル溶液(1g、2.69mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.64mlは実施例1に記載した)。元素分析では、得られた固体はネドクロミル硝酸塩に相当する:
【数10】
【0043】
実施例13:デキストロファン硝酸塩の製造
塩は、アセトニトリル(17ml)中のデキストロファン臭化水素溶液(1g、2.96mmol)に硝酸銀(0.50g、2.96mmol)を加えて製造する。次いで、溶液を30分室温で攪拌する。次に、ろ過して臭化銀の沈殿物を除く。エチルエーテルの透明な溶液を加える(100ml)。沈澱が生じ、これをろ過し、エチルエーテルで洗浄して真空乾燥する。元素分析では、得られた固体はデキストロファン硝酸塩に相当する:
【数11】
【0044】
薬理試験
実施例14:モルモットにおけるセチリジン硝酸塩とセチリジン塩酸塩の抗ヒスタミン活性−実験的な気管支収縮における研究
動物は、心肺活性測量についてのDel Soldatoらの方法(J.Pharmacol. Methods 5 279 1981)にしたがって用意した。ヒスタミン塩溶液0.1ml(2μg/kg)を動物に静脈経路で注射した。各群が8匹の動物からなる3群を形成した。セチリジン硝酸塩、セチリジン塩酸塩又は賦形剤のみを、77μmol/μgの用量で静脈に投与した。
上記のDel Soldatoの参考文献に記載されているようにポリグラフシステムに接続して変えたコンツェット装置によって、カプサイシン投与前後の一回換気量の変化を測定した。
下記の表2に、各処理群における動物の反応を、対照に対する%値として示す。
表に示すように、セチリジン硝酸塩は、セチリジン塩酸塩に対して抗ヒスタミン活性を改善する。
【表2】
【0045】
実施例15:モルモットにおける、デキストロメトルファン塩酸塩、デキストロメトロファン硝酸塩、デキストロファン塩酸塩及びデキストロファン硝酸塩の鎮咳活性
モルモット(体重:430+20)は、Bragaら(Arzneim.Forsch./Drug Res. 43, 550, 1993)によって記載されているように処理した。
この薬理実験では、各8匹の5群を形成した。ひとつの群は処理せず、対象群とした。
各動物を、それぞれ2つの管状の平坦な表面を介したチューブがある円筒状のガラス容器に入れた。このチューブは、それぞれエアロゾルの入り口と出口であった。出口のチューブは、ポリグラフシステムに接続する。
エアロゾルは、水中7.5重量%のクエン酸溶液から形成した。
ガラス容器内の空気の変化は、エアロゾルによって生じる咳の動き(cough stroke)の前後に記録した。1時間後に、生理溶液中のデキストロメトルファン塩酸塩、デキストロメトルファン硝酸塩、デキストロファン塩酸塩とデキストロファン硝酸塩を、110μmol/kgの用量で腹腔内に投与した。注射から30分後に、動物をエアロゾルで処理した。次いで、10分当たりの咳の動きの数を記録した。下記の表3に、対照群を100%として参照した、各処理群から生じた反応の平均を示す。
【表3】
【0046】
表に示すように、デキストロメトルファンとデキストロファンの硝酸塩は、相当する塩酸塩よりも有力な鎮咳剤である。
【0047】
実施例16:マウスにおけるアンブロキソール硝酸塩とアンブロキソール塩酸塩の粘液溶解活性
オスのマウスの粘液溶解活性(mucolitic activity)は、EnglerとZselenyiの方法(J.Pharm.Methods 11, 151, 1984)にしたがって評価した。この方法で、気管分泌物中のフェノールレッドの量を測定する。動物は、生理溶液に溶解した色素を有する500mg/kgの用量であらかじめ腹腔内に投与した。動物各10匹のマウス3群(体重18±2g)を、腹腔内で色素を用いて処理した。ひとつの群を対照群とした。上記の注射の10分前に、2つの処理群それぞれをアンブロキソール硝酸塩又はアンブロキソール塩酸塩264μmol/kgの腹腔内注射に付した。フェノールレッドの注射から30分後に、動物を死なせた。周囲の組織から気管を除き、切開し、生理溶液3mlで30分洗浄した。次いで、1Mの水酸化ナトリウム0.1mlを生理溶液に加えた。洗浄物を、3000rpmで15分遠心分離した。分光光度アッセイを上清について行い、生理溶液中のフェノールレッドの濃度を測定する。粘液溶解活性は、対照群の吸光度を100%と仮定して、それに対する試料の吸光後の%変化として測定した。
表4は、得られた結果を要約している。
【表4】
【0048】
表は、アンブロキソール硝酸塩の粘液溶解活性が相当する塩酸塩の活性より高いことを示している。
【0049】
実施例17:メトロニダゾール硝酸塩の製造
塩は、アセトニトリル(8ml)とテトラヒドロフラン(5ml)からなる溶媒混合物にメトロニダゾール溶液(1g、5.84mmol)を加えて製造する(アセトニトリル中の硝酸溶液1.40mlは実施例1に記載した)。元素分析では、得られた固体はメトロニダゾール硝酸塩に相当する:
【数12】
【0050】
実施例18:イソニアジド硝酸塩の製造
塩は、アセトニトリル(20ml)とテトラヒドロフラン(10ml)からなる溶媒混合物にイソニアジド溶液(2g、14.58mmol)を加えて製造する(アセトニトリル中の硝酸溶液3.50mlは実施例1に記載した)。元素分析では、得られた固体はイソニアジド硝酸塩に相当する:
【数13】
【0051】
実施例19:エリスロマイシン硝酸塩の製造
塩は、アセトニトリル(23ml)とテトラヒドロフラン(17ml)からなる溶媒混合物にエリスロマイシン溶液(2g、2.72mmol)を加えて製造する(アセトニトリル中の硝酸溶液0.65mlは実施例1に記載した)。元素分析では、得られた固体はエリスロマイシン硝酸塩に相当する:
【数14】
【0052】
実施例20:アシクロビル硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(10ml)からなる溶媒混合物にアシクロビル溶液(1g、4.44mmol)を加えて製造する(アセトニトリル中の硝酸溶液1.06mlは実施例1に記載した)。元素分析では、得られた固体はアシクロビル硝酸塩に相当する:
【数15】
【0053】
実施例21:ピラジナミド硝酸塩の製造
塩は、アセトニトリル(10ml)とテトラヒドロフラン(10ml)からなる溶媒混合物にピラジナミド溶液(1g、8.12mmol)を加えて製造する(アセトニトリル中の硝酸溶液1.95mlは実施例1に記載した)。元素分析では、得られた固体はピラジナミド硝酸塩に相当する:
【数16】
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1998MI001743A IT1303671B1 (it) | 1998-07-28 | 1998-07-28 | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
IT98A001743 | 1998-07-28 | ||
PCT/EP1999/005171 WO2000006531A2 (en) | 1998-07-28 | 1999-07-20 | Nitric esters and nitrate salts of specific drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2002521468A JP2002521468A (ja) | 2002-07-16 |
JP2002521468A5 JP2002521468A5 (ja) | 2006-08-31 |
JP4455760B2 true JP4455760B2 (ja) | 2010-04-21 |
Family
ID=11380535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000562338A Expired - Fee Related JP4455760B2 (ja) | 1998-07-28 | 1999-07-20 | 特定の薬物の硝酸エステル及び硝酸塩 |
Country Status (18)
Country | Link |
---|---|
US (3) | US6410791B1 (ja) |
EP (1) | EP1098870B1 (ja) |
JP (1) | JP4455760B2 (ja) |
KR (1) | KR100687806B1 (ja) |
CN (1) | CN1264828C (ja) |
AT (1) | ATE307796T1 (ja) |
AU (2) | AU770313C (ja) |
BR (1) | BR9912375A (ja) |
CA (1) | CA2338854C (ja) |
DE (1) | DE69927977T2 (ja) |
DK (1) | DK1098870T3 (ja) |
ES (1) | ES2252958T3 (ja) |
HU (1) | HUP0102706A3 (ja) |
IL (1) | IL140685A0 (ja) |
IT (1) | IT1303671B1 (ja) |
RU (1) | RU2254330C2 (ja) |
WO (1) | WO2000006531A2 (ja) |
ZA (1) | ZA200100457B (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
IT1303671B1 (it) * | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
IT1317735B1 (it) * | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
US6642276B2 (en) * | 2001-10-01 | 2003-11-04 | M/S Ind-Swift Limited | Controlled release macrolide pharmaceutical formulations |
US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
EP1539679A4 (en) * | 2002-06-28 | 2007-07-04 | Nitromed Inc | OXIM- AND / OR HYDRAZO-CONTAINING, NITROSED AND / OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND USE METHODS |
GB0406069D0 (en) * | 2004-03-17 | 2004-04-21 | Thompson James | Process |
RU2008100237A (ru) * | 2005-06-14 | 2009-07-20 | Джилид Сайэнс, Инк. (US) | ОБЩИЕ ПРОЛЕКАРСТВЕННЫЕ ФОРМЫ СТЕРОИДОВ И β-АГОНИСТОВ (ВАРИАНТЫ), ВКЛЮЧАЮЩИЙ ИХ АЭРОЗОЛЬНЫЙ СОСТАВ (ВАРИАНТЫ) И СПОСОБ ПРЕДОТВРАЩЕНИЯ И/ИЛИ ЛЕЧЕНИЯ ЛЕГОЧНЫХ ВОСПАЛЕНИЙ И/ИЛИ БРОНХОСТЕНОЗА С ИХ ПОМОЩЬЮ |
TW200804241A (en) * | 2006-02-24 | 2008-01-16 | Novartis Ag | New salt |
JP2007275193A (ja) * | 2006-04-04 | 2007-10-25 | Fujifilm Corp | 光プローブおよび光断層画像化装置 |
WO2009142772A2 (en) | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
JP6042197B2 (ja) * | 2012-12-11 | 2016-12-14 | エア・ウォーター株式会社 | 肺障害治療剤 |
CN104211604B (zh) * | 2014-08-18 | 2016-05-11 | 江苏正大清江制药有限公司 | 一种氨溴索与对羟基苯甲酸的共晶及其制备方法 |
CN104211605B (zh) * | 2014-08-18 | 2016-04-27 | 江苏正大清江制药有限公司 | 一种氨溴索与间羟基苯甲酸共晶及其制备方法 |
WO2018089797A1 (en) | 2016-11-14 | 2018-05-17 | Mingwu Wang | Formulations for the treatment of ocular surface diseases and related methods |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2944061A (en) * | 1957-09-20 | 1960-07-05 | Acyl derivatives and process | |
GB865750A (en) * | 1958-09-26 | 1961-04-19 | American Cyanamid Co | Spiro-phosphonium salts |
BE625022A (ja) * | 1961-11-20 | 1900-01-01 | ||
JPS56113748A (en) * | 1980-02-13 | 1981-09-07 | Kowa Co | Aminoethanol derivative and its preparation |
DE3124410A1 (de) * | 1981-06-22 | 1983-01-05 | Heinrich Mack Nachf., 7918 Illertissen | Verfahren zur herstellung von isosorbid-2-nitrat |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
GB9001019D0 (en) * | 1990-01-17 | 1990-03-14 | Euro Celtique Sa | Pharmaceutical aerosol |
US5429825A (en) * | 1992-06-26 | 1995-07-04 | Mcneil-Ppc, Inc. | Rotomelt granulation |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
WO1995007103A1 (en) | 1993-09-07 | 1995-03-16 | The Procter & Gamble Company | Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive |
US5458879A (en) * | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
US5708023A (en) * | 1994-03-28 | 1998-01-13 | The Trustees Of Columbia University In The City Of New York | Zinc gluconate gel compositions |
RU2145595C1 (ru) | 1994-05-10 | 2000-02-20 | Никокс С.А. | Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности |
US6245350B1 (en) * | 1994-12-16 | 2001-06-12 | Warner-Lambert Company | Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process |
US6469009B1 (en) * | 1996-04-08 | 2002-10-22 | Ucb, S.A. | Pharmaceutical compositions for the treatment of rhinitis |
EP0811374A1 (en) * | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
CA2258965A1 (en) | 1996-06-28 | 1998-01-08 | Oxigene, Inc. | Useful formulations of acid addition salt drugs |
TR199901003T2 (xx) * | 1996-10-31 | 1999-07-21 | Schering Corporation | Ast�m tedavisi i�in loratadin ve bir dekonjestan i�eren bile�im. |
DE19721467A1 (de) * | 1997-05-22 | 1998-11-26 | Basf Ag | Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe |
IN188720B (ja) * | 1997-11-06 | 2002-11-02 | Panacea Biotec Ltd | |
DK1041990T3 (da) | 1997-12-23 | 2006-10-02 | Schering Corp | Præparat til behandling af respiratoriske sygdomme og hudsygdomme med mindst en leukotrien-antagonist og mindst et antihistamin |
IT1303671B1 (it) * | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
IT1308633B1 (it) * | 1999-03-02 | 2002-01-09 | Nicox Sa | Nitrossiderivati. |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1311923B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1317735B1 (it) * | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
US20020137764A1 (en) * | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
US6479692B1 (en) * | 2001-05-02 | 2002-11-12 | Nobex Corporation | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof |
ITMI20021392A1 (it) * | 2002-06-25 | 2003-12-29 | Nicox Sa | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' |
-
1998
- 1998-07-28 IT IT1998MI001743A patent/IT1303671B1/it active
-
1999
- 1999-07-20 AU AU52857/99A patent/AU770313C/en not_active Ceased
- 1999-07-20 EP EP99938300A patent/EP1098870B1/en not_active Expired - Lifetime
- 1999-07-20 DE DE69927977T patent/DE69927977T2/de not_active Expired - Lifetime
- 1999-07-20 RU RU2001102262/04A patent/RU2254330C2/ru not_active IP Right Cessation
- 1999-07-20 CA CA2338854A patent/CA2338854C/en not_active Expired - Fee Related
- 1999-07-20 JP JP2000562338A patent/JP4455760B2/ja not_active Expired - Fee Related
- 1999-07-20 US US09/743,808 patent/US6410791B1/en not_active Expired - Fee Related
- 1999-07-20 CN CNB998090425A patent/CN1264828C/zh not_active Expired - Fee Related
- 1999-07-20 AT AT99938300T patent/ATE307796T1/de active
- 1999-07-20 ES ES99938300T patent/ES2252958T3/es not_active Expired - Lifetime
- 1999-07-20 DK DK99938300T patent/DK1098870T3/da active
- 1999-07-20 KR KR1020017000803A patent/KR100687806B1/ko not_active IP Right Cessation
- 1999-07-20 IL IL14068599A patent/IL140685A0/xx not_active IP Right Cessation
- 1999-07-20 HU HU0102706A patent/HUP0102706A3/hu unknown
- 1999-07-20 WO PCT/EP1999/005171 patent/WO2000006531A2/en not_active Application Discontinuation
- 1999-07-20 BR BR9912375-4A patent/BR9912375A/pt not_active Application Discontinuation
-
2001
- 2001-01-16 ZA ZA200100457A patent/ZA200100457B/en unknown
-
2002
- 2002-05-22 US US10/151,955 patent/US6828342B2/en not_active Expired - Fee Related
-
2003
- 2003-12-17 US US10/736,688 patent/US7122539B2/en not_active Expired - Fee Related
-
2004
- 2004-04-07 AU AU2004201457A patent/AU2004201457A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4455760B2 (ja) | 特定の薬物の硝酸エステル及び硝酸塩 | |
TW200940059A (en) | Poly aromatic sodium channel blockers | |
JPH09503214A (ja) | 抗炎症活性及び/又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法 | |
JP2008534480A (ja) | グリコピロニウム塩およびそれらの治療的使用 | |
CZ286621B6 (cs) | Tromethaminová sůl (+)-(S)-2-(3-benzoylfenyl)propionové kyseliny, způsob její výroby a farmaceutický prostředek s jejím obsahem | |
JP2019503993A (ja) | テトラサイクリンの塩 | |
JPH0326183B2 (ja) | ||
JP2002517438A (ja) | 咳の治療のための組成物及び方法 | |
JPH059424B2 (ja) | ||
JPH0140804B2 (ja) | ||
JPH0725724B2 (ja) | トラネキサム酸亜鉛化合物 | |
JPH10502050A (ja) | 骨関節疾患の治療に有用なn−〔{4,5−ジヒドロキシ−及び4,5,8−トリヒドロキシ−9,10−ジヒドロ−9,10−ジオキソ−2−アントラセン−イル}カルボニル〕アミノ酸 | |
JPH0692948A (ja) | 新規なアセタミド誘導体及びその用途 | |
JPS5910563A (ja) | α−(N−ピロリル)−フエニル酢酸誘導体およびその製造方法 | |
US4472424A (en) | Esters of 2-thenoylmercaptopropionylglycine with substituted hydroxybenzenes, process for their preparation and pharmaceutical compositions containing same | |
JPS6362493B2 (ja) | ||
PT90927B (pt) | Processo para a preparacao de (+) 1-{(3,4,5-trimetox)benziloximetil}-1-fenil-n,n-demetil-n-propilamina, util em terapeutica | |
JP2764287B2 (ja) | 胃炎治療剤 | |
JPS6218543B2 (ja) | ||
CN111727039A (zh) | 大肠炎改善剂 | |
JP2001181251A (ja) | アスピリン誘導体、その製造方法、並びにこれを有効成分として含有する抗炎症剤 | |
JPH03505455A (ja) | 新規なウルソデオキシコール酸誘導体 | |
JPS60233053A (ja) | アミノ酢酸誘導体およびその医薬への応用 | |
JPH0374219B2 (ja) | ||
JPH0448777B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060628 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060628 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090721 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091021 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091028 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091221 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100126 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100204 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130212 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |